第三代芳香化酶抑制剂在绝经后乳腺癌新辅助内分泌治疗中的应用

Neoadjuvant endocrine therapy with aromatase inhibitors in the treatment of postmenopausal breast cancer patients

乳腺癌新辅助内分泌治疗是指对非转移性的乳腺癌患者在应用局部治疗前进行的系统性的内分泌治疗。研究证实,第三代芳香化酶抑制剂(Aromatase inhibitors,AIs)应用于绝经后乳腺癌患者的新辅助内分泌治疗效果显著优于他莫西芬(Tamoxifen,TAM),并且能够明显提高局部进展期乳腺癌(Locally advanced breast cancer,LABC)的手术切除率,改善巨大肿瘤和不可手术切除乳腺癌的外科治疗效果。

Neoadjuvant endocrine therapy of breast cancer which is a systemic endocrine therapy method for nonmetastatic breast cancer patients before local treatment. Many studies have confirmed that the effect of neoadjuvant endocrine therapy with aromatase inhibitors is significantly better than that with tamoxifen in the treatment of postmenopausal breast cancer pa- tients. Miniver, it could greatly increase the operable rate for locally advanced breast cancer and improve the effect of the surgical trestment/br large and inoperable breast tumor.